Biosimilars push capitalize on Fresenius Kabi's expanding biosimilars portfolio (vedolizumab and rituximab) to target oncology and autoimmune markets, offering a collaboration or supply arrangement for manufacturing, regulatory support, and co-marketing opportunities.

Blood tech leadership leverage the company’s global leadership in blood collection bags and devices to pursue new contracts with blood banks, hospitals, and transfusion services, including innovative disposables and integrated workflow solutions.

Clinical nutrition footprint target healthcare facilities with Fresenius Kabi’s strong clinical nutrition products, identifying opportunities in enteral and parenteral feeding portfolios to optimize patient nutrition protocols and reduce hospital stay costs.

Infusion and device synergies pursue cross-sell of IV generics, infusion fluids, and MedTech devices (infusion pumps, cell and gene therapy disposables) to inpatient networks, outpatient clinics, and specialty centers focusing on oncology, ICU care, and transplant programs.

Global scale, local wins position for multi-country procurement deals and regional partnerships by highlighting Vision 2026 growth plans, existing global footprint, and digital enablement (cloud, analytics, and supplier platforms) to streamline sourcing, compliance, and lifecycle management.